Seres Therapeutics
MCRB
69 hedge funds and large institutions have $52.5M invested in Seres Therapeutics in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 17 closing their positions.
860% more call options, than puts
Call options by funds: $2.75M | Put options by funds: $287K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
0.24% less ownership
Funds ownership: 2.08% → 1.85% (-0.24%)
10% less funds holding
Funds holding: 77 → 69 (-8)
13% less capital invested
Capital invested by funds: $60.1M → $52.5M (-$7.59M)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$984K |
| 2 |
Millennium Management
New York
|
+$641K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
+$442K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$250K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$850K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$703K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$271K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$189K |
| 5 |
Citigroup
New York
|
-$174K |
MCRB Hedge Fund Activity: Q4 2024 in Review
69 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2024, worth a combined $52.5M — down 13% from $60.1M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MCRB and 9 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 18 added.
The largest buyer was Morgan Stanley, adding an estimated $984K. The largest seller was Fidelity Investments, cutting an estimated $850K.
- 69 institutional investors held Seres Therapeutics (MCRB) as of Q4 2024, down from 77 in Q3 2024.
- Funds reported $52.5M of Seres Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
- 9 funds opened new Seres Therapeutics positions in Q4 2024 and 17 closed out, a net change of -8 holders.
- The largest Seres Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $984K added.
- The largest Seres Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $850K sold.
Based on aggregated 13F filings for Q4 2024.